Minesh P. Mehta, MD, on NSCLC: Tumor Treating Fields for Brain Metastases
2024 ASCO Annual Meeting
Minesh P. Mehta, MD, of Miami Cancer Institute, part of Baptist Health South Florida, discusses results from the METIS (EF-25) trial evaluating the efficacy and safety of tumor treating fields therapy following stereotactic radiosurgery in patients with mutation-negative non–small cell lung cancer (NSCLC) and brain metastases. Tumor treating fields therapy prolongs time to intracranial disease progression and may postpone whole-brain radiation therapy without declines in quality of life and cognition (Abstract 2008).
Transcript
Disclaimer: This video transcript has not been proofread or edited and may contain errors.
It's a pleasure to be here today to talk about the EF-25 METIS trial. This was a clinical trial evaluating the use of tumor treating fields therapy in patients with non-small cell lung cancer with brain metastasis that are mutation negative. Just under 300 patients, 298 to be precise, were randomized to receiving stereotactic radiosurgery, which is the standard of care for these patients, but is characterized with high rate of intracranial relapse. Following stereotactic radiosurgery, patients received best supportive care in the control arm or best supportive care plus tumor treating fields therapy.
The primary endpoint of the trial was to determine if the rate of intracranial progression and the time to intracranial progression could be altered with the use of tumor treating fields therapy. And in fact, the key top line result of the trial was indeed precisely that. The time to intracranial progression was significantly lengthened in favor of tumor treating fields by 10.6 months, and therefore the median time to progression was 10.3 months in the control arm and 21.9 months in the experimental or tumor treating fields arm. This was a significant prolongation.
In association with this prolongation of tying to intracranial progression, quality of life metrics also favored tumor treating fields therapy. There was a greater sustenance of quality of life and a greater durability of quality of life in patients receiving tumor treating fields therapy. Overall, the safety was exceptionally well tolerated. Only 2.3% of patients experienced grade three or higher toxicities that were device related. This is a very well tolerated therapy and prolongs time to intracranial progression, which is the top line result. Other secondary endpoints are currently being evaluated and we look forward to reporting those out shortly.
The ASCO Post Staff
Alex Andrea Francoeur, MD, of UC Irvine Health, discusses data showing an association between the increasing incidence of endometrial cancer and obesity, which disproportionately affects younger women and women of color. According to Dr. Francoeur, the findings warrant targeted health services and public health interventions to stabilize and ultimately reverse the rising rates (Abstract 5507).
The ASCO Post Staff
Thierry Facon, MD, of the University of Lille and Lille University Hospital, discusses phase III findings showing for the first time that isatuximab, an anti-CD38 monoclonal antibody, when given with the standard of care (bortezomib, lenalidomide, dexamethasone, or VRd) to patients with newly diagnosed multiple myeloma who are transplant-ineligible, may reduce the risk of disease progression or death by 40.4% vs VRd alone (Abstract 7500).
The ASCO Post Staff
Emily L. Podany, MD, of Washington University, St. Louis, discusses disparities in the use of PI3K inhibitors for Black patients with estrogen receptor–positive, HER2-negative metastatic breast cancer while other drugs that do not require genomic profiling were similarly used (Abstract 1017).
The ASCO Post Staff
Jonathan E. Rosenberg, MD, of Memorial Sloan Kettering Cancer Center, and Thomas Powles, MD, PhD, of Barts Cancer Institute and the University of London, discuss phase III findings from two studies: the first, investigating enfortumab vedotin-ejfv and pembrolizumab vs platinum-based chemotherapy in previously untreated patients with locally advanced or metastatic urothelial cancer; and the second, looking at nivolumab plus gemcitabine and cisplatin vs gemcitabine and cisplatin alone in patients with lymph node–only metastatic disease enrolled in the CheckMate 901 trial (Abstracts 4581 and 4565).
The ASCO Post Staff
Luciano J. Costa, MD, PhD, of the University of Alabama at Birmingham, discusses recent findings from the CARTITUDE-4 trial showing that, in patients with lenalidomide-refractory functional high-risk multiple myeloma after one prior line of treatment, ciltacabtagene autoleucel improved outcomes vs the standard of care (Abstract 7504).